Sign in
Taking peopleNo phase

Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine

Key facts

Who runs it
Kintampo Health Research Centre, Ghana
Where
Ghana, Kenya, and Malawi4 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
9,280 people, planned
Started
18 Oct 2021
Planned end
30 Apr 2025
Type of study
Observational, 2 groups
Treatments tested
  • Case-control study of clinical outcomes
  • Case-control study of mortality outcome
Record updated
28 February 2025

Who can take part

Age
6 months to 59 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Willingness to participate in study evidenced by written informed consent provided by an adult caregiver
  • Resident in an RTS,S/AS01 implementation area within the catchment area of MVPE sentinel hospitals
  • Eligible, based on date of birth and age, to have received RTSS/AS01
  • Meets the case or control definitions above

Who cannot take part

  • Caregiver not willing to provide consent

This trial is currently available in Ghana, Kenya, and Malawi.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The ongoing Malaria Vaccine Pilot Evaluation (MVPE) is being conducted in Ghana, Malawi and Kenya through community and sentinel hospital surveillance systems and a series of household surveys (to measure vaccine coverage). The Malaria Vaccine Pilot Evaluation-Case Control (MVPE-CC) registered here as observational study is embedded within MVPE comprising case-control studies of clinical and mortality outcomes. Each case will require four controls, and caregiver informed consent will be required prior to study activities.

Read full original descriptionShow less

These observational case control studies will measure as complementary information to what is being collected through MVPE:

1. Safety among children who received the malaria vaccine, with focus on cerebral malaria, meningitis and severe malaria 2. The impact of the malaria vaccine on all-cause mortality for boys and girls, AND 3. Promote use of case-control approaches by Expanded Programmes on Immunization (EPI) and malaria control programmes.

The 2 groups in the trial

  • Case-control study of clinical outcomes

    These are children who live in RTS,S implementation areas aged less than 5 years and who were eligible to have received RTS,S based on their date or birth and age, will be eligible to be recruited into the study. Cases will be recruited in sentinel hospitals of the ongoing malaria Vaccine Pilot Evaluation (MVPE). Control for a case will be a child who lives outside a 100-metre radius from the case, matched on date of birth (+/- 1 month of date of birth of the case)

  • Case-control study of mortality outcome

    These will be children who died of any cause excluding accidents or trauma, who are eligible to have received the RTS,S vaccine based on their date of birth and age. Cases will be recruited from the community-based mortality surveillance of MVPE. Control for a mortality case will be a live child who lives outside a 100 metre radius from the case with date of birth +/- 1 month of the date of birth of the case who are eligible to have received the RTS,S vaccine.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine: Assessment of Safety and Effectiveness Using Case-control Studies Embedded in the Malaria Vaccine Pilot Evaluation
Record updated
28 February 2025